Fig. 1

SHOX2 in TCGA breast cancer patient samples. (a) Higher SHOX2 expression corresponds with significantly worse progression free survival and disease-specific survival. (b) SHOX2 expression is differentially overexpressed in estrogen receptor-negative (ER⁻) breast tumors when compared to estrogen receptor-positive (ER⁺) tumors. **** p < 0.0001. (c, d) Breast tumors deemed “SHOX2-high” tumors (z-score > 1.25) differentially overexpressed transcripts preferentially involved in the epithelial-to-mesenchymal transitioning. (e) SHOX2 expression significantly correlates with the MSigDB Gene Hallmark dataset “EPITHELIAL_MESENCHYMAL_TRANSITION”